MedWatch

Genmab CEO: Three products may turn into five this year

Normally, it takes ten months for a marketing authorization to be processed in the US. Genmab hopes for an accelerated process, so the firm can get approval for two new products this year.

Photo: Tuala Hjarnø / Genmab / PR

Genmab's three winning horses may very well turn into five in the course of 2021.

"The most important milestone this year is that we hope to get two new products approved, which are basically created with Genmab techology. One is Johnson & Johnson's Amivantamab, and the other is Tisotumab Vedotin," Genmab CEO Jan van de Winkel tells Ritzau Finans.

Already a subscriber? Log in.

Read the whole article

Get access for 14 days for free.
No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.

  • Access all locked articles
  • Receive our daily newsletters
  • Access our app
An error has occured. Please try again later.

Get full access for you and your coworkers.

Start a free company trial today

More from MedWatch

Sanofi reduces US insulin prices for the uninsured

While bills to introduce a price cap on insulin are being discussed in the US Senate, Sanofi has beaten them to the punch and reduced the price of insulin products for US diabetes patients without insurance.

Further reading

Related articles

Latest news

See all jobs